Repligen Corp (RGEN) Stock Price, Quote & News

Company Profile

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sampl...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 781 250 0111

Fax: 781 250 0115

Website: www.repligen.com

Address:

Building 1, Suite 100 41 Seyon Street, Waltham, United States

jewell69 Apr. 24 at 1:37 PM

$RGEN pt 207 as of 3/18/26 on stifel focus list RGEN is one of our Select List picks. The stock has stepped down on headlines and questions related to FDA disruption and new modality therapeutic program uncertainty, but we continue to see a solid path towards revenue reacceleration back into the low/mid double digit-range – and in our view the bioprocess market remains the healthiest area of the life sciences space. Shares have dipped below the multi-year (ex-Covid) average on EV/EBITDA, and are not far from the lows experienced during the trough of the bioproduction market slowdown. While the industry-level conversation will remain active, we think company-specific dynamics for RGEN are solid and that the stock screens are favorable within the Tools group right now.

0 · Reply

jewell69 Apr. 24 at 1:35 PM

$RGEN 1st time trade on stifel list. stock lost 8% yesterday 4/23; today is 4/24 at 9:34 am edt 04/24/2026 Buy RGEN REPLIGEN CORP 28 $115.75 -$3,241.00

0 · Reply

freeindeed Apr. 23 at 4:54 PM

https://www.marketbeat.com/instant-alerts/filing-mt-bank-corp-purchases-new-holdings-in-repligen-corporation-rgen-2026-04-23/ $RGEN

0 · Reply

OfficialStocktwitsUser Apr. 2 at 5:08 PM

$RGEN RSI: 57.29, MACD: -4.3829 Vol: 3.90, MA20: 116.88, MA50: 131.90 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

OptionRunners Mar. 27 at 8:22 PM

2 large trades minutes before the close $ESTA roll/adjustment to the May $45 puts and they're not taking any risk off And a $RGEN May $110 call buyer Have a good weekend!

0 · Reply

Tfizzle Mar. 8 at 4:08 PM

$RGEN 134 this week

0 · Reply

Tfizzle Mar. 6 at 8:52 PM

$USO $DJT $QQQ why do I get the feeling with Oil rsi over 80 and overbought that somehow Trump hits pause on WAR over the weekend in full TACO mode? $WHR $RGEN

1 · Reply

Tfizzle Mar. 5 at 10:52 PM

$RGEN multiple bottom today. Temporary bottom is in. 130’s next week

0 · Reply

BillionerOfKing Mar. 4 at 9:20 PM

$RGEN Current Stock Price: $125.83 Contracts to trade: $125.0 RGEN Mar 20 2026 Call Entry: $6.20 Exit: $12.26 ROI: 98% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

SuperGreenToday Feb. 26 at 5:39 PM

$RGEN Share Price: $131.48 Contract Selected: Aug 21, 2026 $130 Calls Buy Zone: $14.96 – $18.48 Target Zone: $24.73 – $30.22 Potential Upside: 56% ROI Time to Expiration: 175 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Repligen to Report First Quarter 2026 Financial Results

Apr 17, 2026, 7:30 AM EDT - 8 days ago

Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network

Mar 18, 2026, 2:15 PM EDT - 5 weeks ago

Repligen Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 10, 2026, 11:20 AM EDT - 6 weeks ago

Repligen Transcript: Leerink Global Healthcare Conference 2026

Feb 24, 2026, 8:30 AM EST - 2 months ago

Repligen Earnings Call Transcript: Q4 2025

Feb 24, 2026, 7:30 AM EST - 2 months ago

Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Feb 10, 2026, 7:30 AM EST - 2 months ago

Repligen to Report Fourth Quarter and Full Year 2025 Financial Results

Jan 13, 2026, 5:15 PM EST - 3 months ago

Repligen Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:30 AM EST - 3 months ago

Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair

Dec 18, 2025, 7:30 AM EST - 4 months ago

Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference

Dec 16, 2025, 7:30 AM EST - 4 months ago

Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows

Dec 3, 2025, 1:20 PM EST - 5 months ago

Repligen Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 26, 2025, 7:30 AM EST - 5 months ago

Repligen Corporation to Present at Evercore Healthcare Conference

Nov 18, 2025, 12:40 PM EST - 5 months ago

Repligen Transcript: Wolfe Research Healthcare Conference 2025

Nov 18, 2025, 8:30 AM EST - 5 months ago

Repligen Transcript: Jefferies London Healthcare Conference 2025

Nov 11, 2025, 10:00 AM EST - 5 months ago

Repligen Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 11:00 AM EST - 5 months ago

Repligen Transcript: UBS Global Healthcare Conference 2025

Oct 28, 2025, 8:30 AM EDT - 6 months ago

Repligen Earnings Call Transcript: Q3 2025

Oct 28, 2025, 7:30 AM EDT - 6 months ago

Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Oct 15, 2025, 7:30 AM EDT - 6 months ago

Repligen to Report Third Quarter 2025 Financial Results

Sep 25, 2025, 6:35 AM EDT - 7 months ago

Repligen Transcript: Bank of America Global Healthcare Conference 2025

Sep 4, 2025, 8:00 AM EDT - 8 months ago

Repligen Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 22, 2025, 7:30 AM EDT - 8 months ago

Repligen Corporation to Present at Upcoming September Conferences

Jul 31, 2025, 10:45 AM EDT - 9 months ago

Repligen Stock Outlook: Risk Skewed To The Downside Through 2026

Jul 31, 2025, 7:30 AM EDT - 9 months ago

Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization

Jul 29, 2025, 8:30 AM EDT - 9 months ago

Repligen Earnings Call Transcript: Q2 2025

Jul 29, 2025, 7:30 AM EDT - 9 months ago

Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Jul 17, 2025, 7:30 AM EDT - 10 months ago

Repligen to Report Second Quarter 2025 Financial Results

Jun 16, 2025, 8:00 AM EDT - 11 months ago

908 Devices Appoints Christopher D. Brown to its Board of Directors

MASS

Jun 3, 2025, 2:20 PM EDT - 11 months ago

Repligen Transcript: 45th Annual William Blair Growth Stock Conference

May 27, 2025, 7:30 AM EDT - 11 months ago

Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report

May 20, 2025, 3:35 PM EDT - 1 year ago

Repligen Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 7, 2025, 7:30 AM EDT - 1 year ago

Repligen Corporation to Present at Upcoming May Investor Conferences

Apr 29, 2025, 8:30 AM EDT - 1 year ago

Repligen Earnings Call Transcript: Q1 2025

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Repligen Reports First Quarter 2025 Financial Results

Apr 8, 2025, 7:30 AM EDT - 1 year ago

Repligen Appoints Jacob Johnson As Vice President Investor Relations

Mar 4, 2025, 1:26 PM EST - 1 year ago

908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth

MASS

Mar 4, 2025, 7:30 AM EST - 1 year ago

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

MASS

Feb 20, 2025, 2:00 PM EST - 1 year ago

Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook

Feb 20, 2025, 8:30 AM EST - 1 year ago

Repligen Earnings Call Transcript: Q4 2024

Feb 11, 2025, 7:30 AM EST - 1 year ago

Repligen to Report Fourth Quarter and Full Year 2024 Financial Results

Jan 14, 2025, 4:30 PM EST - 1 year ago

Repligen Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 7, 2025, 7:30 AM EST - 1 year ago

Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 7:30 AM EST - 1 year ago

Repligen Launches the CTech™ SoloVPE® PLUS System

Dec 16, 2024, 8:11 AM EST - 1 year ago

BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

BLFS

Dec 12, 2024, 7:30 AM EST - 1 year ago

Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report

Dec 9, 2024, 7:30 AM EST - 1 year ago

Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns

Nov 20, 2024, 11:00 AM EST - 1 year ago

Repligen Transcript: Stephens 26th Annual Investment Conference | NASH2024

Nov 19, 2024, 12:40 PM EST - 1 year ago

Repligen Transcript: Stifel 2024 Healthcare Conference

Nov 14, 2024, 10:15 AM EST - 1 year ago

Repligen Transcript: UBS Global Healthcare Conference 2024

Nov 12, 2024, 1:19 PM EST - 1 year ago

Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth

Nov 12, 2024, 8:30 AM EST - 1 year ago

Repligen Earnings Call Transcript: Q3 2024

Nov 5, 2024, 7:30 AM EST - 1 year ago

Repligen Corporation to Present at Upcoming Investor Conferences

Oct 14, 2024, 11:15 AM EDT - 1 year ago

Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More

Sep 24, 2024, 7:30 AM EDT - 1 year ago

Repligen Opens Training & Innovation Center to Elevate Customer Experience

Sep 6, 2024, 8:45 AM EDT - 1 year ago

Repligen Transcript: 2024 Wells Fargo Healthcare Conference

Aug 23, 2024, 7:30 AM EDT - 1 year ago

Repligen Corporation to Present at Wells Fargo Healthcare Conference

Aug 16, 2024, 11:46 AM EDT - 1 year ago

Exclusive: Repligen in bid for reagent vendor Maravai, sources say

MRVI

Jul 31, 2024, 2:50 PM EDT - 1 year ago

These Analysts Revise Their Forecasts On Repligen Following Q2 Results

Jul 30, 2024, 12:01 PM EDT - 1 year ago

Repligen Lowers Guidance On China Weakness, Analyst Expects

Jul 30, 2024, 8:30 AM EDT - 1 year ago

Repligen Earnings Call Transcript: Q2 2024

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Repligen Reports Second Quarter 2024 Financial Results

Jul 29, 2024, 4:00 PM EDT - 1 year ago

Repligen Announces Agreement to Acquire Chromatography Innovator Tantti

Jul 16, 2024, 7:30 AM EDT - 1 year ago

Repligen to Report Second Quarter 2024 Financial Results

Jun 26, 2024, 8:44 AM EDT - 1 year ago

This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

HOOD PAGS UHS X

Jun 21, 2024, 8:22 AM EDT - 2 years ago

Top 3 Health Care Stocks That Could Blast Off In June

ENOV PEN

Jun 13, 2024, 7:00 AM EDT - 2 years ago

Repligen Announces CEO Transition Plan

Jun 6, 2024, 11:30 AM EDT - 2 years ago

Repligen Transcript: Jefferies Global Healthcare Conference

Jun 5, 2024, 1:00 PM EDT - 2 years ago

Repligen Transcript: The 44th Annual William Blair Growth Stock Conference

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing

May 30, 2024, 9:40 AM EDT - 2 years ago

Repligen Transcript: 2024 Leerink Partners Healthcare Crossroads Conference

May 22, 2024, 7:30 AM EDT - 2 years ago

Repligen Corporation to Present at Upcoming June Investor Conferences

May 14, 2024, 10:30 AM EDT - 2 years ago

Repligen Transcript: 2024 RBC Capital Markets Global Healthcare Conference

May 1, 2024, 8:30 AM EDT - 2 years ago

Repligen Earnings Call Transcript: Q1 2024

May 1, 2024, 7:30 AM EDT - 2 years ago

Repligen Reports First Quarter 2024 Financial Results

Apr 17, 2024, 7:30 AM EDT - 2 years ago

Repligen to Report First Quarter 2024 Financial Results

Mar 20, 2024, 3:00 PM EDT - 2 years ago

Repligen Transcript: KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Mar 19, 2024, 7:30 AM EDT - 2 years ago

Repligen Appoints Maggie A. Pax to Board of Directors

Feb 21, 2024, 8:30 AM EST - 2 years ago

Repligen Earnings Call Transcript: Q4 2023

Feb 21, 2024, 7:30 AM EST - 2 years ago

Repligen Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 7, 2024, 7:30 AM EST - 2 years ago

Repligen to Report Fourth Quarter and Full Year 2023 Financial Results

Jan 9, 2024, 5:15 PM EST - 2 years ago

Repligen Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Nov 16, 2023, 11:00 AM EST - 2 years ago

Repligen Transcript: Stephens Annual Investment Conference | NASH 2023

Nov 15, 2023, 8:00 AM EST - 2 years ago

Repligen Transcript: Stifel 2023 Annual Healthcare Conference

Oct 31, 2023, 8:30 AM EDT - 2 years ago

Repligen Earnings Call Transcript: Q3 2023

Sep 8, 2023, 10:15 AM EDT - 2 years ago

Repligen Transcript: Wells Fargo Securities Healthcare Conference 2023

Aug 2, 2023, 8:30 AM EDT - 2 years ago

Repligen Earnings Call Transcript: Q2 2023

May 2, 2023, 8:30 AM EDT - 3 years ago

Repligen Earnings Call Transcript: Q1 2023

Mar 21, 2023, 1:30 PM EDT - 3 years ago

Repligen Transcript: KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Feb 22, 2023, 8:30 AM EST - 3 years ago

Repligen Earnings Call Transcript: Q4 2022

Jan 10, 2023, 5:15 PM EST - 3 years ago

Repligen Transcript: JPMorgan Healthcare Conference

Nov 1, 2022, 8:30 AM EDT - 3 years ago

Repligen Earnings Call Transcript: Q3 2022

Sep 20, 2022, 8:15 AM EDT - 3 years ago

Repligen Transcript: Investor Day 2022

Aug 2, 2022, 6:49 AM EDT - 4 years ago

Repligen Earnings Call Transcript: Q2 2022

Apr 27, 2022, 8:55 AM EDT - 4 years ago

Repligen Earnings Call Transcript: Q1 2022

Feb 17, 2022, 8:30 AM EST - 4 years ago

Repligen Earnings Call Transcript: Q4 2021

Oct 27, 2021, 8:00 PM EDT - 4 years ago

Repligen Earnings Call Transcript: Q3 2021

Jul 27, 2021, 3:39 PM EDT - 5 years ago

Repligen Earnings Call Transcript: Q2 2021

May 4, 2021, 7:53 AM EDT - 5 years ago

Repligen Earnings Call Transcript: Q1 2021

Feb 24, 2021, 8:30 AM EST - 5 years ago

Repligen Earnings Call Transcript: Q4 2020

Nov 5, 2020, 8:30 AM EST - 5 years ago

Repligen Earnings Call Transcript: Q3 2020

Jul 30, 2020, 8:30 AM EDT - 6 years ago

Repligen Earnings Call Transcript: Q2 2020

May 13, 2020, 8:00 AM EDT - 6 years ago

Repligen Transcript: AGM 2020

jewell69 Apr. 24 at 1:37 PM

0 · Reply

jewell69 Apr. 24 at 1:35 PM

$RGEN 1st time trade on stifel list. stock lost 8% yesterday 4/23; today is 4/24 at 9:34 am edt 04/24/2026 Buy RGEN REPLIGEN CORP 28 $115.75 -$3,241.00

0 · Reply

freeindeed Apr. 23 at 4:54 PM

https://www.marketbeat.com/instant-alerts/filing-mt-bank-corp-purchases-new-holdings-in-repligen-corporation-rgen-2026-04-23/ $RGEN

0 · Reply

OfficialStocktwitsUser Apr. 2 at 5:08 PM

0 · Reply

OptionRunners Mar. 27 at 8:22 PM

2 large trades minutes before the close $ESTA roll/adjustment to the May $45 puts and they're not taking any risk off And a $RGEN May $110 call buyer Have a good weekend!

0 · Reply

Tfizzle Mar. 8 at 4:08 PM

$RGEN 134 this week

0 · Reply

Tfizzle Mar. 6 at 8:52 PM

$USO $DJT $QQQ why do I get the feeling with Oil rsi over 80 and overbought that somehow Trump hits pause on WAR over the weekend in full TACO mode? $WHR $RGEN

1 · Reply

Tfizzle Mar. 5 at 10:52 PM

$RGEN multiple bottom today. Temporary bottom is in. 130’s next week

0 · Reply

BillionerOfKing Mar. 4 at 9:20 PM

0 · Reply

SuperGreenToday Feb. 26 at 5:39 PM

0 · Reply

OfficialStocktwitsUser Feb. 26 at 12:04 AM

$RGEN RSI: 29.95, MACD: -6.7014 Vol: 7.96, MA20: 141.94, MA50: 155.44 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

ZacksResearch Feb. 25 at 3:42 PM

$RGEN just delivered the kind of quarter bulls wait for. Q4 EPS topped estimates, and revenues surged 18% Y/Y — driven by solid organic growth and stronger margins heading into 2026. That’s not just a beat… that’s momentum building. 🚀 Discover what’s fueling the growth story here 👉 https://www.zacks.com/stock/news/2874936/repligens-q4-earnings-beat-estimates-revenues-surge-yy?cid=sm-stocktwits-2-2874936-teaser-35074&ADID=SYND_STOCKTWITS_TWEET_2_2874936_TEASER_35074

0 · Reply

ZacksResearch Feb. 25 at 2:42 PM

$RGEN beats earnings, but lagging the industry rally — is it time to hold? 📊 The company reported Q4 EPS of 49 cents, topping estimates with an 18% year-over-year revenue increase. However, shares have only risen 11% in the past six months compared to the industry's 23.3% rally. Discover the full breakdown here 👉 https://www.zacks.com/stock/news/2874936/repligens-q4-earnings-beat-estimates-revenues-surge-yy?cid=sm-stocktwits-2-2874936-body-35071&ADID=SYND_STOCKTWITS_TWEET_2_2874936_BODY_35071

0 · Reply

StocktwitsEarnings Feb. 24 at 12:39 PM

$RGEN Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.24 up 140.00% YoY • Reported revenue of $197.91M up 18.12% YoY • Repligen expects full year 2026 revenue of $810M to $840M, representing 10% to 14% reported growth and 9% to 13% organic growth, alongside 150 bps adjusted operating margin expansion.

0 · Reply

TSFStocks Feb. 18 at 8:19 PM

$RGEN

0 · Reply

SuperGreenToday Feb. 9 at 8:08 PM

$RGEN Share Price: $142.49 Contract Selected: Jun 18, 2026 $140 Calls Buy Zone: $13.86 – $17.12 Target Zone: $24.01 – $29.34 Potential Upside: 64% ROI Time to Expiration: 128 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

AlgorithmicAdvisors Feb. 4 at 11:49 AM

$RGEN is a life sciences tools company with a dominant position in cell culture; growth is solid but decelerating as biopharma capex softens.

0 · Reply

Estimize Feb. 4 at 11:01 AM

Wall St is expecting 0.45 EPS for $RGEN Q1 [Reporting 05/05 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co

0 · Reply

SuperGreenToday Jan. 29 at 4:44 PM

$RGEN Share Price: $154.66 Contract Selected: Jun 18, 2026 $155 Calls Buy Zone: $13.94 – $17.22 Target Zone: $22.98 – $28.08 Potential Upside: 56% ROI Time to Expiration: 139 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Estimize Jan. 19 at 12:03 PM

Wall St is expecting 0.44 EPS for $RGEN Q4 [Reporting 02/25 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co

0 · Reply

OfficialStocktwitsUser Jan. 6 at 4:28 PM

$RGEN RSI: 72.29, MACD: 2.5962 Vol: 4.18, MA20: 163.33, MA50: 159.25 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

KaleKing Dec. 25 at 9:35 AM

$RGEN Risk premia compress only when proof accumulates, because growth without leverage now attracts skepticism. A coherent operating roadmap would be catalytic.

0 · Reply

Market Cap	6.43B
Revenue (ttm)	738.26M
Net Income (ttm)	48.89M
EPS (ttm)	N/A
PE Ratio	72.75
Forward PE	63.31
Profit Margin	6.62%
Debt to Equity Ratio	0.00

Volume	1,236,200
Avg Vol	940,210
Day's Range	N/A - N/A
Shares Out	56.40M
Stochastic %K	25%
Beta	1.19
Analysts	Strong Sell
Price Target	$179.50